Enhanced intestinal transit due to lipopolysaccharide (LPS) is reversed by cannabinoid (CB) 2 receptor agonists in vivo, but the site and mechanism of action is unknown. We have tested the hypothesis that CB 2 receptors are expressed in the enteric nervous system and are activated in pathophysiological conditions. Tissues from either saline or LPS treated (2h; 65µg/kg, i.p.) rats were 
Introduction
The actions of cannabis and related compounds on gastrointestinal (GI) function have been known for Centuries (17; 56) . They are generally inhibitory, reducing motility and secretion throughout the gut in both physiological and pathophysiological conditions (12; 24; 25; 50; 54) . After the discovery and cloning of the cannabinoid (CB) receptors (22) , the CB 1 receptor emerged as the primary CB receptor expressed in both the central and peripheral nervous system, including the enteric nervous system (ENS) of the gut. In contrast, CB 2 receptor expression was thought to be restricted to cells and organs of the immune system (21; 29) . However, recent data have substantially altered our view of the distribution of CB receptors, which are much more widely distributed than originally described. This includes the presence of CB 1 receptors on nonneural tissues such as liver and adipose tissue and CB 2 receptor expression in the brain (7; 23; 30; 76).
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Whereas the presence of the CB 1 receptor within the ENS has been well characterized (11; 25; 57) , there are relatively few studies on CB 2 receptor localisation or actions in the GI tract (84). Although CB 2 receptor mRNA has previously been reported in the stomach and ileum (13; 66) , there is little evidence for a functional role for CB 2 receptors in the normal GI tract (for review see Ref (83)). More is known about the actions of CB 2 receptors under pathophysiological conditions. In experimental models of colitis (mustard oil and dextran sulphate sodium), the CB 2 receptor agonist JWH133 attenuated the severity of colitis, presumably by modulating the CB 2 receptor immunoreactive infiltrates that were observed in both these models (28) . These data are in partial agreement with a reported upregulation of CB 2 receptors on the epithelium and immune cells of colonic tissues from patients with inflammatory bowel disease (IBD)(80). CB 2 receptors may also play a role in visceral hypersensitivity associated with IBD, since in a 2,4,6-trinitrobenezesulphonic (TNBS) model of colitis, the CB 2 receptor agonist JWH015 abolished colitis-induced hyperalgesia, however, the site of action of this protective effect is unknown (63).
Our group reported that in a model of lipopolysaccharide (LPS)-enhanced GI transit (39) , CB 2 receptor activation was able to return the accelerated motility to baseline levels. Although we speculated that this involved the ENS, the presence of the CB 2 receptor in the ENS had not been established at that time (38) . In the present study, we tested the hypothesis that CB 2 receptors are expressed in the ENS and are activated in pathophysiological conditions. Our aims were to determine if CB 2 receptors were expressed in the ENS of the GI tract and could be upregulated by LPS. In addition, we sought to determine if CB 2 receptor activation could modulate neuronal activation and transmission in LPS treated animals.
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Materials and Methods
Animals
Male Sprague Dawley rats (250-350g; Charles River, Quebec, Canada) and female CB 2 receptor gene-deficient (CB 2 -/-) mice backcrossed onto a C57Bl6/N background and age and strain matched controls from the same facility were used for all studies (5) . Animals were housed in plastic sawdust floor cages with free access to Purina Laboratory chow and tap water. Animal use for these experiments was approved by the University of Calgary Animal Care Committee and all protocols were carried out in accordance with the guidelines of the Canadian Council on Animal Care.
Contractility studies
Rats were treated with an intraperitoneal (i.p.) injection or either saline or lipopolysaccharide (LPS from Salmonella typhosa, Sigma-Aldrich, St Louis, MO, USA; Lot # 074K4011, 65 µg/kg, i.p.), 2 hours later they were euthanized with sodium pentobarbital (>65 mg/kg; i.p.), and a 10 cm segment of ileum was removed and placed in ice-cold Krebs solution consisting of (in mM) 117 NaCl, Once the experimental protocol was finished, the tissue response to 10 -4 M bethanechol was again tested and the average response was calculated. In all cases, tissues responded well at the end of the experiment and no preparations were removed due to reduced viability. At the end of the study, tissues were removed from the bath, the silk removed, the lumen opened and mucosa scraped off. The muscle tissue was weighed to obtain a wet weight, then dried and reweighed to obtain the dry weight.
CB 2 receptor mRNA detection and quantification
Rats were injected i.p. with either saline or LPS (65 µg/kg). After 2 hours the animals were euthanized with sodium pentobarbital (>65 mg/kg i.p.) and intracardially perfused with 1L/kg phosphate-buffered saline (PBS) to remove the blood. The spleen and ileum were then harvested. The ileum was used as full- 
Western blotting
Rats treated with either saline or LPS (n=5 per group; 2h, i.p.) and untreated wildtype or CB 2 -/-mice (n=3/group) were euthanized with sodium pentobarbital (>65 mg/kg i.p.) and intracardially perfused with PBS at 4°C. Full wall thickness ileum samples were collected from mice whereas in rats, full-wall thickness ileal segments, muscle and submucosal layers of the ileum and the ileal mucosa were collected and homogenized in protease inhibitors and protein concentrations were determined. Proteins were loaded at 60 µg of the extracted protein of each tissue and separated using SDS-PAGE (12%), using a constant current of 30 mA/gel. Molecular weight markers (161-0373, Bio-Rad Laboratories, Inc., Hercules, CA, USA) were used in each gel. After separation, the proteins were transferred from the SDS-PAGE gel onto a nitrocellulose membrane as previously described (42) . Membranes were then incubated in blocking solution composed of 5% fat-free milk and tris-buffered saline (TBS-T) for 
Enteric neuron and glial activation
We modified the in vivo LPS inflammatory model protocol used previously (37) to allow us to establish if enteric neurons or glia were activated by LPS, and to determine whether this could be modulated by a CB 2 receptor agonist. Rats were treated with either saline or LPS at 0 minutes, drugs (vehicle, cannabinoid agonists and/or antagonists) were administered at 80 min, and at 120 min the animals were euthanized with sodium pentobarbital (>65 mg/kg i.p.) and a 10 cm segment of ileum was removed. The ileal segment was immediately placed on a Sylgard plate containing PBS with 1 µM nifedipine to prevent muscle contraction, the tissue was then opened along the mesenteric border, pinned flat with the mucosa facing up and fixed overnight in Zamboni's fixative and processed for Fos immunohistochemistry. Tissues were minimally handled in order to decrease mechanical stimulation.
Quantification of Fos immunoreactive neurons and glia
To 
Statistics
Data were analyzed using a two-way ANOVA followed by Bonferroni-corrected t-tests.
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Results
CB receptor agonists and contractility after LPS treatment
We isolated ileal tissues and determined the effects of the cannabinoid ligands on the cholinergic contractile response elicited by electrical field stimulation (EFS). The contractile responses evoked by EFS were completely blocked by atropine (data not shown), so were due to acetylcholine release from enteric nerves.
In animals treated with LPS, there was an enhanced contractile response that reached 122.7 ± 5.0% of the contractile response seen in saline-treated rats (n=9). Thus we could mimic the enhanced motility seen in vivo (36) . The CB 2 receptor agonist JWH133 had no effect on contractile responses in the saline treated tissues when compared to vehicle control (n=4; P>0.05) (Fig. 1) . In transcription confirming the amplified product was not due to genomic DNA in the RNA sample (data not shown). These samples were processed for quantitative real time RT-PCR to determine if LPS treatment was able to upregulate the CB 2 message (Fig. 2B) . There was no increase of CB 2 receptor message in the spleen or the mucosa. In the full-wall thickness and muscle and submucosal samples, the LPS-treated tissues sometimes displayed increases in the CB 2 receptor mRNA expression, but there was no statistically significant increase in the group data (n=5, P>0.05).
CB 2 receptor protein is expressed in the rat ileum
CB 2 receptor protein was detected in full-wall thickness ileum, and was also present in the muscle and submucosal layers and in the mucosa ( Figure 2C ). The molecular weight of the detected bands was ~60 kDa, which is an appropriate size based on previously published work (3; 45). In order to confirm the specificity of the antibodies used, we performed studies in ileum from wildtype and CB 2 -/-mice. In mouse ileal tissue, only the CB 2 receptor antibody from Alpha Diagnostics recognized the same molecular weight band observed in rat ileal tissues ( Figure 2C ). In the CB 2 -/-mice labeling was completely absent, indicating antibody specificity. As before, we compared the tissues from LPS and saline treated rats. Analysis by densitometry of CB 2 /actin ratio content for each sample indicated that CB 2 receptor expression was not upregulated in the rat ileum by LPS treatment (Fig. 2D) .
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CB 2 receptor is expressed by enteric neurons
We used many different antibodies directed against the C-terminus of the CB 2 receptor to localize CB 2 receptor expression in the ENS. Despite robust validated neuronal expression in the CNS (45) and by Western blot in the GI tract, the Alpha Diagnostics antibody did not produce consistent labeling in the ENS.
Similarly, antibodies from Affinity Bioreagents, Alexis and Santa Cruz either did not label the ENS or produced a clearly non-specific pattern of immunoreactivity. In contrast, a C-terminal affinity-purified antibody that we made (against residues 326-342 of rat CB 2 receptor), identified CB 2 receptor immunoreactivity in enteric neurons and nerve fibres in both the myenteric (Fig.   3 ) and submucosal plexus (data not shown) in rat and mouse ileum. This labeling was absent in CB 2 -/-mouse ileum (Fig. 3D ), that were subsequently double-labeled with calretinin to confirm the presence of enteric ganglia.
Further control studies where the primary or secondary antibodies were used alone did not produce any staining (data not shown).
We assessed whether specific classes of enteric neurons expressed the CB 2 receptor using double-labeling immunohistochemistry (Fig. 4) . CB 2 receptor immunoreactivity was found in many cells that expressed the pan-neuronal markers NSE (Fig. 4 , top row), PGP 9.5 (data not shown) and calretinin, a marker of longitudinal muscle motor neurons and primary afferent neurons (6; 21) (Fig. 4 , Duncan et al. CB 2 receptors in the ENS. 20 center row). However, only the minority of neurons that express neuronal nitric oxide synthase were found to colocalize with the CB 2 receptor (Fig. 4, bottom row). Double-labeling of the CB 2 receptor with the glial-specific markers S-100 (Fig. 5) or glial fibrillary acidic protein (GFAP; data not shown), revealed no CB 2 receptor expression in these separate cell populations. Double-labeling with synaptotagmin, a marker for synaptic vesicles found in nerve terminals, showed a degree of colocalization (Fig. 5) , suggesting the CB 2 receptors are present on both nerve terminals and in neurons of the ENS.
Activation of the CB 2 receptor reduces Fos expression in the ENS
We used Fos expression to ascertain whether in LPS-treated rats we could observe direct evidence for activation of enteric neurons (27; 30; 44) . LPS caused a significant increase in Fos expression in both enteric neurons and enteric glia when compared to tissues from saline-treated control rats ( Fig. 6; P<0.001). When animals were co-injected with the CB 2 receptor agonist JWH133
(1 mg/kg), activation of both enteric neurons and glia were significantly provide confirmatory evidence in the rat for the observation that CB 1 receptor agonists inhibit acetylcholine release and contractility in the guinea pig myenteric plexus (9; 16; 32). We also were able to confirm that CB 2 receptor activation had no effect on contractility in saline-treated rats. In the LPS-treated tissues, contractile activity was enhanced; this may account for the enhanced GI transit observed in vivo (22) and so this preparation provides a good model to Duncan et al. CB 2 receptors in the ENS. 22
further explore these findings. The CB 2 receptor agonist JWH133, which had no effect under basal conditions, normalized the LPS-enhanced cholinergic contractile responses. Since this is an isolated tissue preparation, it would appear to rule out the central CB 2 receptors present in the brain-gut axis (42) and would indicate that the site of action is localised to the gut, and most likely the ENS. Our data are in agreement with other studies that report no actions of CB 2 receptor activation in GI motility under physiological conditions (10; 17) .
However, a recent study reported that CB 2 receptor activation inhibits cholinergic neurotransmission in the normal mouse stomach (26), consistent with older observations where EFS-induced relaxant responses were enhanced in rat gastric fundus in the presence of the CB 2 receptor antagonist AM630 (41) . In the stomach, it appears that CB 2 receptors are functional under normal conditions, whereas in the ileum these receptors appear to be active only after an inflammatory stimulus. These results indicate differences in constitutive cannabinoid receptor activity between stomach and intestine.
The results from the current study do not explain the lack of actions of CB 1 receptor activation in the LPS-enhanced transit model in vivo (22) . As expected,
we saw an inhibition of contractility in the isolated vehicle-treated ileum by the CB 1 receptor agonists ACEA and WIN55,212-2, however, we also observed a similar inhibition in the LPS treated tissues. Currently, we do not have an explanation for these observations, except to highlight the many potential sites spinal cord slices (2; 37), but the mechanism has not yet been determined in these systems, While it is known that CB 2 receptors inhibit adenylyl cyclase and regulate of mitogen-activated protein (MAP) kinase (13), a possible action via these signaling pathways remains to be determined in the myenteric plexus.
We designed an experimental protocol to allow us to evaluate whether LPS can induce myenteric neuronal activity, and to determine whether CB 2 receptor activation can modulate neuronal activation. Fos expression can be used to examine enteric neuron activation in response to a various stimuli (27; 30; 44) , and in our hands, LPS induces a robust Fos expression in enteric neurons. The fact that enteric glia were also activated was unexpected. Both enteric neuron and glial Fos expression were attenuated by in vivo activation of CB 2 receptors by JWH133. The ability of JWH133 to return the Fos expression to basal levels is in agreement with the contractility studies where twitch responses were returned to control levels. We speculate that LPS is stimulating the ENS (correlated with increased Fos expression and contractility) either directly or indirectly and CB 2 receptors return both of these evoked changes back to the baseline conditions.
Presumably, the increased glial Fos expression is secondary to neuronal activation since it can be reduced by CB 2 receptor agonists in the absence of we have shown that enteric glia can alter ileal contractility in vitro and GI transit in vivo (27) .
In conclusion, we report that CB 2 receptors are expressed on enteric neurons. immunoreactivity is shown in the second column and the overlay doublelabeled image is shown in the third column. There is no colocalization between S100 and CB 2 receptor immunoreactivity; the distinct cell populations are shown using thin arrows. There is some degree of colocalization with CB 2 receptor immunoreactivity and synaptotagmin, double-labeling is shown using thick arrows, no colocalization is shown using thin arrows. Scale bar 100µm. AM630 (C, F) which has no effect alone on LPS-induced Fos expression. Scale bar 100µm.
